P. Baumann

Discipline

Psychologie (4) Méthodes et statistiques (1) Linguistique (1)

Type de document

Articles (17) Livres et chapitres d'ouvrages (3) Recensions (2) Colloques et conférences (2) Mémoires, Thèses et HDR (1)

Co-auteur

Date

Source

Mot-clé

Patients (8) Human beings (8) Patients (8) Treatment (7) Psychoses (6) Older people (6) adulte (5) plasma (5) adulte (5) dose (4) Development (4) Psychiatry (4) Months (4) Management (4) Drugs (4) Use (4) administration (3) puits (3) pharmacocinétique (3) littérature (3) ordre (3) taux (3) jeune (3) Methods (3) Drug monitoring (3) Symptoms (3) State, The (3) Political science (3) Pharmacokinetics (3) Order (3)

Documents écrit par P. Baumann (20) | parle de P. Baumann (0)

Nöropsikofarmakolojide Terapötik İla ç İzlemi İ çin Ortak Görü ş Kılavuzu: 2017 G üncellemesi
C. Hiemke et al. (2024)
Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.
P. Baumann et al.
Citalopram in vitro metabolism in a Beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?
B. Rochat et al.
Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.
C.B. Eap et al.
Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication.
L. Alameda et al. (2020)
Cannabis, a Significant Risk Factor for Violent Behavior in the Early Phase Psychosis. Two Patterns of Interaction of Factors Increase the Risk of Violent Behavior: Cannabis Use Disorder and Impulsivity; Cannabis Use Disorder, Lack of Insight and Treatment Adherence.
V. Moulin et al. (2018)
Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia.
A. Delacrétaz et al. (2018)
Age at the time of onset of psychosis: A marker of specific needs rather than a determinant of outcome?
P. Golay et al.
Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment.
P. Golay et al.
Diffusion spectrum imaging connectomics: a biomarker for staging in psychotic disorders
A. Griffa et al.
Integrity of the fornix-hippocampus circuit and relationship with peripheral oxidative stress markers in early phase psychosis
P. Baumann et al.
Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort.
M.T. Koller et al. (2013)
Challenge of transition in the socio-professional insertion of youngsters with neurodisabilities  
P. Baumann (2012)
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
C. Hiemke et al. (2011)
Die Schweizerische Transplantationskohortenstudie (STCS)
M. Kohler et al. (2009)
Apport de la pharmacogénétique dans le traitement médicamenteux des addictions : l'exemple de la méthadone
C.B. Eap et al. (2006)
Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.
C.B. Eap et al. (2004)
Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects
C.B. Eap et al. (2004)
Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry.
C.B. Eap et al. (1998)
Allgemeine Grundlagen der Pharmakokinetik und Pharmakodynamik
T. Buclin et al. (1992)